Enrolling by InvitationPhase 4ketamine

Ketamine Infusion for Neuropathic Pain in Brachial Plexus Injuries

Sponsored by Mayo Clinic

NCT ID
NCT04933149
Target Enrollment
100 participants
Start Date
2021-12-15
Est. Completion
2026-12

About This Study

The purpose of this study is to assess pre- and postoperative neuropathic pain in patients with traumatic brachial plexus injuries to determine if intraoperative ketamine infusion affect neuropathic pain associated with avulsion injuries of the brachial plexus.

Conditions Studied

Brachial Plexus Injury

Interventions

  • Ketamine Infustion

Eligibility

Age:18 Years - N/A
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria:

* Patients with neuropathic pain associated with avulsion injuries following traumatic brachial plexus injuries scheduled for brachial plexus exploration and reconstruction by three senior surgeons at Mayo Clinic (AYS, ATB, RJS):
* Neuropathic pain defined as pain directly related to injury to the somatosensory system, and score \>4/10 on the Douleur Neuropathique en 4 Questions (DN4) neuropathic pain questionnaire. Symptoms of neuropathic pain include allodynia, hyperalgesia, burning, needle-like, throbbing, shooting, or electrical-type sensation.
* Nerve root avulsion on CT myelogram.
* Traumatic brachial plexus injuries defined as blunt or penetrating trauma resulting in injury and dysfunction along the course of the brachial plexus defined as nerve roots C5-T1, trunks, divisions, cords, and terminal branches.

Exclusion Criteria:

* Patients without pain following traumatic brachial plexus injuries.
* Patients with brachial plexus injuries due to non-traumatic causes such as tumors, infection, radiation, or inflammatory disorders such as Parsonage Turner Syndrome.
* Patients who do not require surgery for exploration/reconstruction at the brachial plexus.
* Patients under 18 years of age.
* Contraindication to ketamine use (severe hepatic dysfunction -cirrhosis, high-risk coronary artery disease, poorly controlled psychiatric condition- schizophrenia.

Study Locations (1)

Mayo Clinic in Rochester
Rochester, Minnesota, United States

Interested in this trial?

Contact the study team to learn more about eligibility and enrollment.

View on ClinicalTrials.gov
Data Source
ClinicalTrials.gov

Last updated from source